Curaxis Pharmaceutical (Curaxis Pharmaceutical) Equity-to-Asset : -12.55 (As of Dec. 2011)

View and export this data going back to . Start your Free Trial

What is Curaxis Pharmaceutical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Curaxis Pharmaceutical's Total Stockholders Equity for the quarter that ended in Dec. 2011 was $-8.26 Mil. Curaxis Pharmaceutical's Total Assets for the quarter that ended in Dec. 2011 was $0.66 Mil.

The historical rank and industry rank for Curaxis Pharmaceutical's Equity-to-Asset or its related term are showing as below:

CURXQ's Equity-to-Asset is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.59
* Ranked among companies with meaningful Equity-to-Asset only.

Curaxis Pharmaceutical Equity-to-Asset Historical Data

The historical data trend for Curaxis Pharmaceutical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaxis Pharmaceutical Equity-to-Asset Chart

Curaxis Pharmaceutical Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Equity-to-Asset

-1.80

-12.28

-11.31

-12.55

Curaxis Pharmaceutical Semi-Annual Data
	Dec08	Dec09	Dec10	Dec11
Equity-to-Asset	-1.80	-12.28	-11.31	-12.55

Competitive Comparison of Curaxis Pharmaceutical's Equity-to-Asset

For the Drug Manufacturers - General subindustry, Curaxis Pharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curaxis Pharmaceutical's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curaxis Pharmaceutical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Curaxis Pharmaceutical's Equity-to-Asset falls into.

Curaxis Pharmaceutical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Curaxis Pharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2011 is calculated as

Equity to Asset (A: Dec. 2011 )	=	Total Stockholders Equity	/	Total Assets
	=	-8.26	/	0.658
	=

Curaxis Pharmaceutical's Equity to Asset Ratio for the quarter that ended in Dec. 2011 is calculated as

Equity to Asset (Q: Dec. 2011 )	=	Total Stockholders Equity	/	Total Assets
	=	-8.26	/	0.658
	=

Curaxis Pharmaceutical (OTCPK:CURXQ) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Curaxis Pharmaceutical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Curaxis Pharmaceutical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaxis Pharmaceutical Corp (OTCPK:CURXQ) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.curaxispharma.com

Curaxis Pharmaceutical Corp was incorporated in Delaware on February 27, 2001. It is a specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease. The Company's therapeutic platform is based on the hypothesis that diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. Its discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable it to develop significant new treatments for Alzheimer's disease and may have applications for many cancers.

Executives

Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Michael W George	director	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Headlines

No Headlines